Hebei Senlang Biotechnology Inc., Ltd.

This early-stage study tests a new treatment called S103 for people with multiple myeloma that has returned or stopped responding to standard therapies. S103 uses a patient's own immune cells, modified to target and attack the cancer. The main goals are to check safety and find t…

This study tests a new treatment called S101 for people with a rare and aggressive blood cancer (T-Lymphoblastic Leukemia/Lymphoma) that has come back or not responded to standard therapy. The treatment uses a patient's own immune cells, which are modified in a lab to recognize a…

This study tests a new treatment using a patient's own immune cells, modified to target and attack faulty immune cells that cause autoimmune diseases. It is for people with severe lupus or other autoimmune conditions that have not responded to standard therapies. The goal is to c…